The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis

31 May 2010 • by Natalie Aster

GBI Research’s new report “The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis” provides an essential source of data and analysis on the global autoimmune disease therapeutics market with coverage on the market landscape, key market trends, market drivers and restraints. The report identifies the key trends shaping and driving the dynamism in the global autoimmune disease therapeutics market. The report also provides an insight in to the prevalent competitive landscape, product pipeline supplemented with key company profiles.

The Global Autoimmune Disease Therapeutics Market is Forecast to Show Steady Growth over the Forecast Period

The global autoimmune disease therapeutics market was valued to be $32 billion in 2008 and expected to grow to $48 billion with a CAGR of 6% by year 2015. Approximately 3.3 million patients received pharmacological treatment for autoimmune diseases with average cost of therapy being $12,545 per year. The patient volume appears to be increasing at a slow rate of 0.6% per year. In addition, the average annual cost of therapy for autoimmune therapeutics appears to be increasing at a higher rate over the forecast period and is expected to reach an approximate value of $13,400 by 2015. As a result, the autoimmune disease therapeutic market value is going to see a steady increase over the time period 2008 – 2015.

Increasing Acceptance of Biologics as First Line of Treatment Set to Increase the Average Treatment Costs for Autoimmune Disorders

GBI Research analyzed environmental and industry trends to assess the market evolution. The therapeutic capabilities of biologics in controlling and treating autoimmune complications are allowing pharmaceutical manufacturers to commence label extensions of their present portfolio of biologics for multiple autoimmune complications. Biologics like Enbrel, Humira and Remicade have proved to be blockbuster drug due to their higher efficacy profiles. These drugs have recently gained popularity over the traditional treatment options. Currently the market is dominated by the other traditional chemotherapies. In the year 2008 the biologics had a share of about 35% of the autoimmune market with 65% owned by the traditional chemotherapy options. But the scenario is expected to undergo a drastic change with time.

Presence of High levels of Unmet Need within Autoimmune Disease Sectors

The current therapeutic options available in the autoimmune sector includes various kinds of treatment options like immunosuppressant, anti-inflammatory drugs, anti-cancer drugs, anti- malarial drugs, DMARDs, NSAIDs and most importantly the biologics. Even with this wide variety of the available treatment options the autoimmune market sector is facing a very high level of unmet patient need. The Biologics in the various autoimmune disease sectors witness high levels of efficacy but are not very safe. The other Chemotherapies don not have good efficacy. The fact that diseases like MS, RA and many others have no cure creates a huge unmet need. This trend has its advantages and disadvantages. For the pharmaceutical company it opens a huge scope for R&D yet it reduces the market growth as the patients prefer alternative therapies.

About GBI Research

GBI Research is a leading business information company providing global business information reports and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.